Hexarelin
NOT FDA APPROVEDGrowth-hormone secretagogue
Also known as: Examorelin
Not FDA approved. Sold as a research chemical, labelled not for human consumption.
Early evidence, mostly unproven in humans
- Regulatory standing. Sold as a research chemical, not approved
- Limited human data. Some human data exists, not conclusive
- No registered human trials. Nothing registered on ClinicalTrials.gov
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven: it is a potent trigger of GH release in humans. Key limitation: the body desensitises to it quickly, blunting effect over time. Body-composition benefits are not established.
What it is
A potent GH-releasing peptide (GHRP) acting on the ghrelin receptor.
What the research says
Human data show strong GH release, but rapid desensitisation limits sustained effect.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Hexarelin in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT.
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans.
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
Growth hormone secretagogue binding sites in peripheral human tissues.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Hexarelin is the intervention being tested.
No interventional studies for Hexarelin are registered on ClinicalTrials.gov. That is not proof it is unsafe or useless, but it means the human evidence here does not come from registered clinical trials, the exact gap the marketing tends to hide.
FDA recalls & enforcement
Hexarelin has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Rapid tolerance / desensitisation.
- Can affect cortisol and prolactin at higher doses.
- Gray-market purity varies.
Doses reported in studies & protocols
No established clinical dose. This is not a recommendation.
Purity reality
A COA is the only way to confirm content.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.